Vimarsana
Biggest News Aggregation in the World

Energy Isotope Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Energy Isotope Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Energy Isotope Program Today - Breaking & Trending Today

Scientists Investigate Astatine's Interactions with Ion Exchange and Chromatography Resins - Vimarsana News

Scientists Investigate Astatine's Interactions with Ion Exchange and Chromatography Resins

Astatine is one of the least-studied elements of the Periodic Table, because all isotopes of astatine are unstable, with the longest half-life barely exceeding 8 hours.

Source: azom.com
New Understanding of Astatine's Chemical Propert - Vimarsana News

New Understanding of Astatine's Chemical Propert

Astatine-211 is a promising alpha emitter for targeted alpha therapy for cancer, but astatine is among the least-studied elements. In this research, scient

Agreement to spur US production of iridium isotope : Corporate - Vimarsana News

Agreement to spur US production of iridium isotope : Corporate

A joint product agreement between the US Department of Energy Isotope Program and QSA Global Inc is intended to lead to the re-establishment of domestic production of iridium-192. The USA has been dependent on imports of the isotope for the last 20 years.

Serva Energy Discovers Promising New Way to Produce Cancer-killing Actinium-225 Isotope - Vimarsana News

Serva Energy Discovers Promising New Way to Produce Cancer-killing Actinium-225 Isotope

/PRNewswire/ -- Serva Energy, a nuclear innovation company, has developed a new production method to ramp up the supply of Actinium-225, a cancer-killing...

POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update - Vimarsana News

POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update

13.05.2022 - POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada for Phase 1 therapeutic trial for PNT6555, the ...